


As peripécias da metila na Química Medicinal



Química
med
Medicinal
chem

A Química Farmacêutica Medicinal no Brasil: Novas Perspectivas no Ensino e Pesquisa

Eliezer J. Barreiro

Professor Titular

Universidade Federal do Rio de Janeiro

Laboratório de Avaliação e Síntese de Substâncias Bioativas

www.farmacia.ufrj.br/lasbio



Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos
(INCT-INOVAR)
www.inct-inofar.ccs..ufrj.br

Minha homenagem aos Professores de Química Farmacêutica Medicinal

Química
med
Medicinal
chem


THE ROLE OF THE MEDICINAL
CHEMIST IN DRUG DISCOVERY —
THEN AND NOW

Joseph G. Lombardino* and John A. Lowe III† 2011- ACS Award in Industrial Chemistry (ziprasidone)

MedChem



Joseph G. Lombardino



“...medicinal chemists today live in exciting times... their work can have a beneficial effect on millions of suffering patients – surely an important motivating factor for any scientist...”




The Role of the Medicinal Chemist in Drug Discovery – Then and Now,


Nature Rev. Drug Disc. 2004, 3, 853.

Inovações Terapêuticas


Química
med
Medicinal
chem




propranolol
1964



cimetidina
1975




captopril
1987




celecoxibe
1999


12 GF's




indinavir
1996




simvastatina
1986



imatinibe
2001




Inovações Terapêuticas



"Fifty percent of the currently used drugs contain at least one aromatic ring that can be matter of substitution"

J Taylor

A metila *natureba*...



1805 - F. Setürner
1925 - R. Robinson




1947

morphine
ED₅₀ = 4.8 mg/kg

* JV Braun, *Ber. Dtsch. Bot. Ges.* 1914, 47, 2312

A ausência da metila...







Lipofilicidade
3B

* JV Braun, *Ber. Dtsch. Bot. Ges.* 1914, 47, 2312


As metilas *na* morfina...

Índice de atividade analgésica





Dioscoride. Description of opium to collect opium from the poppy seed head

As admiráveis metilas da floresta...



Virolas amazônicas
Índios & indóis

Alcalóides Indólicos




3-indolil-etilaminas

efeitos alucinogênicos

3 metilas

Similaridade molecular



A extravagância da metila...




Epipedobates tricolor



John W. Daly

1933-2008

Un. Maryland, EUA




(-)-epibatidine (natural)

First natural chemotype:
7-azabicyclo[2.2.1]heptane


nAChR

organochloride
alkaloid




(+)-epibatidine

Molecular similarity



(-)-*N*-methylepibatidine
(natural)



(+)-*N*-methylepibatidine

J W Daly, "Ernest Guenther Award in Chemistry of Natural Products. Amphibian Skin: A Remarkable Source of Biologically Active Arthropod Alkaloids", *J. Med. Chem.* **2003**, *46*, 445-452




J W Daly, "Thirty Years of Discovering Arthropod Alkaloids in Amphibian Skin", *J. Nat. Prod.* **1998**, *61*, 162-172



Editorial, *J Nat Prod* **2010**, *73*, 300

A incrível leveza da metila...




Lead Optimization



C. G. Wermuth, Aminopyridazines – an alternative route to potent muscarinic agonists with no cholinergic syndrome, *Il Farmaco* **1993**, 48, 253-274


A metila *enigmática*...

3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles




Química
med
Medicinal
chem

central serotonin (5-HT) reuptake inhibition
& α_2 -adrenoceptor blocking activity






J I Andrés *et al.*, Discovery of a New Series of Centrally Active Tricyclic Isoxazoles Combining Serotonin (5-HT) Reuptake Inhibition with α_2 -Adrenoceptor Blocking Activity, *J Med Chem* 2005, 48, 2054.


Mais um capricho da metila ...




Cadeia do aciclovir



TR



A metila que não podia faltar...




National Historic Chemical Landmarks

AMERICAN CHEMICAL SOCIETY

A new era of logical drug design

The research program leading to cimetidine also represented a revolution in the way pharmaceuticals are developed. Traditionally, the development of a new drug would often depend on the fortuitous discovery of a plant or microbial extract that showed some of the required biological activity. Using that first extract as a lead, many similar compounds would be made and tested for pharmacological effectiveness. In many cases, the researchers did not know how the drug worked, so finding an optimal compound was difficult.


The development of cimetidine was radically different: it was one of the first drugs to be designed logically from first principles. SK&F's multidisciplinary research team first looked at the physiological cause of acid secretion. They confirmed that a molecule found in the body called histamine triggers the release of acid when it binds to a specific receptor (now called the H₂-receptor) in the stomach lining. Their aim was to find a molecule that successfully competed with histamine in combining with the receptor, but then blocked, rather than stimulated, acid release. Such a molecule was called a histamine H₂-receptor antagonist and represented a new class of drugs.




cimetidine



1988



James W. Black



C Robin Ganellin



John C Emmett




Graham J Durant

A metila muito *inteligente*..

Dois sub-tipos de H_R C Robin Ganellin, 1973

Interações fracas




Forma A

$a = 4,83 \text{ \AA}$
 $b = 5,52 \text{ \AA}$


Forma B

Equilíbrio tautomérico




4-metil-histamina

efeito da metila



2-metil-histamina

inibição receptores H₁ = 17%
 inibição receptores H₂ = < 2%



Análogo ativo

4-metil-histamina


inibição receptores H₁ = 0,2%
 inibição receptores H₂ = 50%



A sagacidade da suave metila...

Primeiro antagonista seletivo do receptor histaminérgico H₂

Inovação
terapêutica




1st blockbuster



1975

> US\$ 1 bi




cimetidina




Smith, Kline and French
(SK&F)
(atual GSK)

Química
med
Medicinal
chem



A (bis)metila astuta...



John R. Vane
(1927-2004)



K. Sune Bergström
(1916-2004)

molecular
modification

Química
med
Medicinal
chem


enhancing
metabolic stability



1982



Bengt I. Samuelsson




Misoprostol



* A Robert & BJ Magerlein, *Adv Biosci* 1973, 9, 247


A metila *entra*...




in vitro antimalarial activity against chloroquine-sensitive (Sierra Leone D-6) and resistant (Indochina W-2) clones of *P. falciparum*

LRS Dias, ACC Freitas, EJ Barreiro, DK Goins, D Nanayakkara, JD McChesney, Synthesis and biological activity of new potential antimalarial: 1*H*-pyrazolo[3,4-*b*]pyridine derivatives. *Boll. Chim. Farm.* **2000**, *139*, 14

A homologia, a metila e os *nossos* aminoácidos





A homologia da valina




isoleucina


valina



Os amino ácidos homólogos e a COX




Sítio secundário




$\text{C}_5\text{H}_{11}\text{NO}_2$
Valina

b.





COX-2

- Inflamação
- Câncer
- Endotélio vascular
- Rins
- Cérebro



Ácido araquidônico
 $K_m = 5,6/5,4 \mu\text{M}$

c.






$\text{C}_6\text{H}_{13}\text{NO}_2$
Isoleucina

COX-1

- Estômago
- Plaquetas
- Rins


A metila mágica... (the magic methyl)




COX-1

Molecular similarity

diclofenac




lumiracoxib



celecoxib

COX-2

A genialidade da metila mágica ...



DICLOFENAC
 Ki (μM) PGHS-1 = 0.010
 Ki (μM) PGHS-2 = 0.018
COX-1

LUMIRACOXIB
 Ki (μM) PGHS-1 = 3.2
 Ki (μM) PGHS-2 = 0.06
COX-2
 2003 (2008)




Química
 medicinal
chem


Lumiracoxib have one chlorine substituted by fluorine and the phenylacetic acid moiety has methyl group in *meta* position

H. Furuie et al., The evaluation of the COX-2 selective inhibition of lumiracoxib, a novel nonsteroidal anti-inflammatory drug, *Clin Pharmacol Therap* 2004, 75, P5

The Molecular Basis of COX-2 Versus COX-1 Selectivity of Lumiracoxib




COX-1




COX-2

Molecular Docking Studies



CM Corrêa *et al.*, The Molecular Basis of COX-2 Versus COX-1 Selectivity of Lumiracoxib by Molecular Docking Studies, *Letters in Drug Design & Discovery*, 2007, 4, 422

O discreto *charme* da metila...



S S Adams*

TIPS 2012, 33, 1
10.1016/j.tips.2011.10.007



A member of Alliance Boots



Diversity and modularity of GPCR protein-coupled receptor structures



*S S Adams, The propionic acids: A personal perspective", *Journal of Clinical Pharmacology* 1992, 32, 317-323.




IT Harrison, *J Med Chem* 1970, 13, 203



R Noyori





2001




in vivo

σ





química nova



& V L E Lima, Os fármacos e a quiralidade: uma breve abordagem, *Quim Nova* 1997, 20, 657-663.

Química
med
Medicinal
chem

PGHS-2




COX-2 seletivo
Searle

Vida-média = **12 dias!**
(ADME)



metabolismo

th_ierapeutic
i_nnovation



nova possível indicação:
câncer colo retal

Celecoxibe (SC-58634)


1999

[1998 - Dr Mario G Cardozo (na USP)]


TD Penning *et al.*, *J. Med. Chem.* **1997**, 40,1347

O mercado mundial de fármacos antiinflamatórios (ca. 50; 2012) ~ US\$ 10 bi

A sofisticação da metila...



Indian researchers in the 1951



Química
med
Medicinal
chem

methaqualone
Mandrax^R



Anticonvulsivant Activity (Rat)[&]

(R)-(+)-methaqualone $ED_{50} = 35,7$ mg/Kg


(S)-(-)-methaqualone $ED_{50} = 26,5$ mg/Kg

US Patent 3135659 - Hydroxy and Alkoxy Aryl Quinazolones

Atropoisomerismo



(M)-enantiomer




(P)-enantiomer

& A. Mannschreck *et al.*, The enantiomers of methaqualone and their unequal anticonvulsive activity, *Eur. J. Med. Chem.* **1984**, 19, 381



AR Santos *et al.*, Atropoisomerismo: o efeito da quiralidade axial em substâncias bioativas, *Quim Nova* **2007**, 30, 125; SR LaPlante, PJ Edwards, LD Fader, A Jakalian, O Hucke, Revealing Atropisomer Axial Chirality in Drug Discovery, *ChemMedChem* **2011**, 6, 505

Novos inibidores da COX-2 bispirazólicos^{a)}



^{a)} M P Veloso, Tese de Doutorado, Instituto de Química, UFRJ, 2000

Synthesis and Characterization of the Atropisomeric Relationships of a Substituted *N*-Phenyl-Bipyrazole Derivative with Anti-inflammatory Properties

MARCIA P. VELOSO,^{1,2,3} NELILMA C. ROMEIRO,⁴ GILBERTO M. S. SILVA,^{1,5,6} HÉLIO DE M. ALVES,¹ ANTONIO C. DORIGUETTO,⁷ JAVIER ELLENA,⁸ ANA L. P. MIRANDA,^{1,5} ELIEZER J. BARREIRO^{1,2,5} AND CARLOS A. M. FRAGA^{1,2,5*}

¹Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil

²Programa de Pós-Graduação em Química, Instituto de Química, Universidade Federal do Rio de Janeiro, RJ, Brazil

³Faculdade de Ciências Farmacêuticas, Universidade Federal de Alfenas, Alfenas, MG, Brazil


⁴Universidade Federal do Rio de Janeiro, Macaé, RJ, Brazil

⁵Programa de Pós-Graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, RJ, Brazil


⁶Instituto de Pesquisa Clínica Evandro Chagas, FIOCRUZ, Rio de Janeiro, RJ, Brazil

⁷Instituto de Ciências Exatas, Universidade Federal de Alfenas, Alfenas, MG, Brazil



⁸Instituto de Física de São Carlos, Universidade de São Paulo, São Carlos, SP, Brazil




ABSTRACT: This work describes the atropisomeric relationships of 3-methyl-5-(3-methyl-5-phenyl-1H-pyrazol-1-yl)-1-phenyl-1H-pyrazol-4-amine (2d), which belongs to series 4-aminobipyrazole derivatives designed as anti-inflammatory agents. The ¹H-NMR spectra obtained in the presence of a chiral lanthanide shift salt associated to chiral HPLC analysis, X-ray diffraction and molecular modeling tools confirmed that ortho bis-functionalized bipyrazole 2d exists as a mixture of aR,aS-atropisomers. These results provide useful information to understand the pharmacological profile of this derivative and of other 4-aminobipyrazole analogues.



Determinação da configuração absoluta





Lichosorb (N. 738342) RP-18 column (250 mm x 4 mm x 5 μm)
 L-7450A diode array detector (DAD)
 acetonitrile and water (adjusted to pH 3 with TFA 0.1%) gradients
 [CH₃CN:HOH (pH 3) from 20:80 to 80:20]



Enraf-Nonius Kappa-CCD diffractometer

A elegante *sutileza* da metila...

therapeutic
innovation



**Inovação
terapêutica**



1988 – Nicholas Lydon, Brian J. Druker
& Charles L Sawyers &

1995 - Compound STI571 ++

2001 – Imatinib (Gleevec[®], [Novartis](#))[[link](#)]

New molecular
pattern

chronic myelogenous leukemia
(CML)

 **NOVARTIS**




imatinibe



Nicholas B. Lydon
Blueprint Medicines Inc

**Química
med
Medicinal
chem**

 OREGON
HEALTH & SCIENCE
UNIVERSITY



Brian J. Druker*
Blueprint Medicines Inc

 **HHMI**
HOWARD HUGHES MEDICAL INSTITUTE




Charles L. Sawyers**

& 2009 - Lasker Foundation Clinical Award (*J. Clin. Invest.* **2009**, *119*, 2863; DOI:10.1172/JCI41141);

* Brian J. Druker has been awarded with the 2012 Japan Prize in Healthcare and Medical Technology;

** Charles L. Sawyers was named in 2011, Thomson Reuters Citation Laureate in Medicine;



HTS



arylamines library
(privileged structure)


1990

K_i PKC




PKC and TK inhibitor
(Bcr-Ablk inhibitor)

methyl
addition





> Bcr-Ablk selectivity
< PKC

Conformational effect



chronic myelogenous leukemia (CML)

Tinibes







therapeutic innovation



gsk

lapatinibe
2007



2011- crisotinibe
2012- bosutinibe



- US market in 2009: US\$ 18,5 bi *
- Imatinibe world sales in 2009: US\$ 4,0 bi*

* S Aggarwal, Nature Rev Drug Discov 2010, 9, 427



As metilinha\$ bilionária\$...

Akira Endo, Sankyo Co

1975 – **Mevastatina (ML-263b)**

A.Endo, *J. Med. Chem.* 1985, 28, 1



Estatinas*

Protótipo natural

Similaridade molecular



A.Endo, *J. Antibiot.* 1976, 29, 1346

Penicillium citrinum


Idem, *Ibid*, 1979, 32, 852

Monascus ruber

(compactina)

Mevalolactona
HMG-CoA redutase

Química Medicinal



JL Goldstein



MS Brown



1985 LDL

University of Texas, Dallas

Lovastatin (MK-803)

1978 – Merck & Co.

Aspergillus terreus

1987 – MS&D (**Mevacor^R**)

1988 – **Mevacor^R** US\$ 260 mi




Arthur A Patchett

Alfred Burger Award 2002

J. Med. Chem. 1986, 29, 849



A metila *se* achando...




mevastatin

IC_{50} HMG-CoA_R = 5.6 nM

lovastatin

IC_{50} HMG-CoA_R = 2.2 nM

Química
med
Medicinal
chem



simvastatin

IC_{50} HMG-CoA_R = 0.9 nM



PS Anderson, Reflexions on
medicinal chemistry at
Merck, West Point,
Annu. Rept. Med. Chem.
2012, 47, 3

Arthur A Patchett
J Med Chem 2003, 45, 5609


Estatinas

5-HMGC_oARI

2ª geração



Top selling drug in history



Bruce D Roth




3ª geração

Química medicinal

O mercado mundial de estatinas é estimado em US\$ 23 bilhões (2013)


A "metilinha" do LASSBio...

(ah!) Final




LASSBio-294

IC₅₀ (PDE4B) > 100 μM



LASSBio-785


IC₅₀ (PDE4B) = 30 μM




metila

Química
med
Medicinal
chem

LASSBio
Laboratório de Avaliação e Síntese de Substâncias Bioativas




Conformação "grampo-de-cabelo"




Conformação em "U"

A metilinha sabe-tudo...



Novo protótipo Al dual^{b)}... e metilado!^{a)}



In vivo



a) A. E. Kümmerle *et al.*, Design, Synthesis, and Pharmacological Evaluation of *N*-Acyldrazones and Novel Conformationally Constrained Compounds as Selective and Potent Orally Active PDE-4 Inhibitors, *J Med Chem* **2012**, *55*, 7525; b) X Jalencas & J Mestres, On the origins of polipharmacology, *MedChemComm* **2013**, *4*, 80.



15 Da


C-H $\mu = 0,4 \text{ D}$

δ^+ / R^+



$\pi = 0,22$

$\sigma_{\text{meta}} = 0,51 / \sigma_{\text{para}} = 0,52$


Rekker const = 0,702



“The methyl group, so often considered as chemically inert, is able to alter deeply the pharmacological properties of a molecule.”



Camille G. Wermuth



Química
med
Medicinal
chem

Salve, salve “metilinha” poderosa ...

CHEMICAL REVIEWS

Chem. Rev. 2011, 111, 5215–5246

IF (2011) = 40,19

REVIEW

pubs.acs.org/CR

The Methylation Effect in Medicinal Chemistry

Eliezer J. Barreiro,^{*,†,‡,§} Arthur E. Kümmerle,^{||,†,§} and Carlos A. M. Fraga^{†,‡,§}



[†]Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, CCS, Cidade Universitária, CP 68.006, 21941-902 Rio de Janeiro, RJ, Brazil

[‡]Programa de Pós-Graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Cidade Universitária, Ilha do Fundão, Rio de Janeiro, RJ, Brazil

[§]Programa de Pós-Graduação em Química, Instituto de Química, Universidade Federal do Rio de Janeiro, Cidade Universitária, Ilha do Fundão, Rio de Janeiro, RJ, Brazil

Química
e
Medicinal

dx.doi.org/10.1021/cr200060g

LASSBio
Laboratório de Avaliação e Síntese de Substâncias Bioativas

www.uff.br/RVQ





<http://ejb-eliezer.blogspot.com.br/>

Obrigado

ejbarreiro@ccsdecania.ufrj.br

Praia do Boqueirão, Saquarema, RJ